Bull&Bear | Bull Stocks Surge with NXTT and RGC Leading Gains, While Bearish Sentiment Hits IOVA and ORGO

In the realm of bull stocks, several companies have shown impressive performances recently.

Next Technology (NXTT) has experienced a remarkable increase, with its shares surging by 661.29% over three consecutive days and an astonishing 699.73% over the past three days. The company has disclosed holding approximately 5,833 bitcoins valued at around $481.7 million as of March 31, 2025, a significant rise from the 833 bitcoins it held as of December 31, 2024.

GIBO Holdings (GIBO), part of the Global Currency IBO Group, a unique and integrated AIGC animation streaming platform, recently completed a business merger with Bukit Jalil Global Currency Acquisition 1 Limited.

Brain Regeneration Technologies (RGC) continues its impressive performance, with its shares climbing 72.65% and maintaining a five-day streak, culminating in a 497.57% increase over the past five days. Since the beginning of the year, Brain Regeneration Technologies' stock price has surged by over 6681%.

Webuy Global (WBUY) saw a remarkable rise in its share price by 59.21% over three days, with a staggering increase of 9239.93% in the same period. The company has resumed its listing on the Nasdaq Capital Market and has returned to profitability, driven by strong growth in the first quarter.

The Beauty Health Company (SKIN) saw its shares rise by 50.81%. The increase followed the company’s announcement of first-quarter financial results that exceeded expectations.

On the bearish side, some stocks have faced declines.

Iovance (IOVA) shares dropped by 44.79% after JMP Securities downgraded the company to a market perform rating from an outperform rating.

Organogenesis (ORGO) experienced a 42.70% decrease in its stock price. The decline was attributed to the company's first-quarter financial results falling short of expectations, with adjusted earnings per share at $(0.11), missing the anticipated $(0.06), and sales at $86.7 million, below the expected $90.77 million.

Protalix (PLX) witnessed a decline of 40.48% as its first-quarter earnings per share came in at $(0.05), missing the expected $0.03, while sales were $10.11 million, below the anticipated $21.60 million.

DocGo (DCGO) shares fell by 39.91% over two consecutive days, with a two-day decline of 41.67%. The drop followed reports of first-quarter financial results underperforming expectations and a downward revision in the sales guidance for the fiscal year 2025. Needham reduced its target price for the stock from $4 to $3.

CVRx (CVRX) faced a 38.69% decline in its stock price as JPMorgan downgraded the company to an underweight rating and lowered its target price to $7.